AstraZeneca acquires Neogene for 200M USD
Cambridge-based British-Swedish multinational pharmaceutical and biotechnology major AstraZeneca has informed that it has completed the acquisition of Amsterdam-based biotechnology company Neogene.
Neogene will operate as a wholly-owned subsidiary of AstraZeneca, with operations in Amsterdam, the Netherlands, and California, the United States, the company announced in a media statement on January 16, 2023.
AstraZeneca said that it has acquired all outstanding equity of Neogene in exchange for an initial payment of 200 million US dollars.
- Ipsen to acquire Albireo for $952 million Paris-based French biopharmaceutical company Ipsen announced on January 9, 2023, that it has entered into a merger agreement with Boston-based Albireo for 952 million dollars, |
- SS Innovations goes global, acquires Avra Medical Robotics SS Innovations, an Indian Medtech Start-up Company, has gained access to the global market through acquisition of controlling interest in Avra Medical Robotics |
Under the terms of the agreement, AstraZeneca will pay up to 120 million US dollars in additional contingent milestone-based and non-contingent consideration, the statement read.
AstraZeneca stated that it is developing a cell therapy portfolio aimed at empowering and equipping the T cells of the immune system to fight cancer more effectively.
The company further stated that it is building on the work already done in blood cancers where chimeric antigen receptor T-cell (CAR-T) therapies, a type of living medicine created by isolating and modifying a patient’s T cells to targeting their specific tumour, are being used to treat some haematological malignancies.